NRIX
Nurix Therapeutics, Inc.Healthcare · $2.5B market cap
Verdict
We can't put a fair value on NRIX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow NRIX
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 2, 2026: no open-market purchases, 2 sales worth $149K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Ring Christine
Chief Legal Officer · 2026-09-02
Sold
$11K
Ring Christine
Chief Legal Officer · 2026-09-02
Sold
$138K
Other filings
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works